177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 247 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Spectacular Breast Cancer Awareness Calendar Showcases Survivors’ Stories, Told with Body... October 17, 2019 For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge January 8, 2020 FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 Load more HOT NEWS FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT... FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor...
